Sun Pharmaceutical Industries Limited updates on Mohali facility

The US FDA had conducted inspection at Sun Pharmaceutical Industries Limited's Mohali (Punjab) facility from August 3 to August 12, 2022. The US FDA had classified the inspection as "Official Action Indicated" (OAI). The Company has received a letter titled "CONSENT DECREE CORRESPONDENCE / NON-COMPLIANCE LETTER" from the US FDA. US FDA has directed the Company to take certain corrective actions at the Mohali facility before releasing further final product batches into the US. These actions include, among others, retaining an independent CGMP expert to conduct batch certifications of drugs manufactured at the Mohali facility.

The Company is taking required corrective steps, but there will be a temporary pause in release of batches from Mohali until US FDA mandated measures are implemented. US shipments from Mohali will resume once these measures are in place.

Shares of Sun Pharmaceutical Industries Limited was last trading in BSE at Rs. 989.15 as compared to the previous close of Rs. 987.65. The total number of shares traded during the day was 80893 in over 1713 trades.

The stock hit an intraday high of Rs. 993.00 and intraday low of 985.40. The net turnover during the day was Rs. 79904641.00.

Source : Equity Bulls

Keywords

SunPharmaceuticalIndustries INE044A01036 MohaliFacility USFDA Inspection